CN Creative Appoints Chief Financial Officer
CN Creative Ltd.
04.04.2012 11:00
---------------------------------------------------------------------------
MANCHESTER, England, 2012-04-04 11:00 CEST (GLOBE NEWSWIRE) --
CN Creative, Ltd. (CNC), a healthcare company providing innovative and
sustainable solutions to reduce smoking and smoking-related illnesses, today
announced that Tim Byrne has been appointed Chief Financial Officer.
Mr. Byrne, who is a Fellow of the Institute of Chartered Accountants, is an
accomplished financial executive whose experience ranges from start-up ventures
to international publicly listed companies. Most recently, he was a Founding
Partner of The Management Alliance, which provides strategic and financial
consulting and management services. Previously, Mr. Byrne was CEO and CFO of
Airtours plc, a FTSE 250 listed company with diversified global operations and
an annual turnover of [Pounds]5.2 billion.
CN Creative markets a portfolio of products and services for smoking cessation
and harm reduction. The company's Nicadex(tm) electronic inhaler nicotine
replacement therapy (NRT) is to commence clinical trials shortly and the
company intends to submit a Marketing Authorisation Application to the UK
Medicines and Healthcare products Regulatory Agency (MHRA) later this year.
Regulatory submissions in other European territories and the US will follow.
'Tim's extensive experience in growing global firms is proving invaluable, and
we are delighted to have him as part of CNC's management team,' said David
Newns, co-founder and Company Director of CN Creative. 'His broad expertise is
especially helpful as we are advancing our pioneering electronic inhaler
nicotine replacement therapy towards MHRA submission, while also expanding our
existing businesses in the UK and overseas.'
Dale R. Pfost, PhD, Chairman of CN Creative and a General Partner at Advent
Ventures, commented, 'Tim brings us a global financial perspective and a keen
appreciation of how to manage the challenges of high growth companies, and he
is well-grounded in the nuts and bolts of implementing the financial management
systems critical to our success.'
About CN Creative
CN Creative has developed a portfolio of products and services focused on harm
reduction and smoking cessation, including user-friendly nicotine delivery
systems and patient-focused smoking cessation and support services, such as
QuitDirect, the Intellicig(r) electronic cigarette, ECOpure high purity nicotine
preparations and NRT Direct. CNC's Nicadex(tm) electronic inhaler nicotine
replacement therapy product is in development for use as part of medically
supervised smoking cessation programmes. For more information, visit
www.cncbio.co.uk.
CONTACT: CN Creative
Media
Barbara Lindheim, BioCom Partners
blindheim@biocompartners.com, +1 212 584-2276
Corporate
David Newns, CN Creative
david.newns@cncbio.com, +44 (0) 7834 767 367
News Source: NASDAQ OMX
04.04.2012 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: CN Creative Ltd.
GroÃbritannien
Phone:
Fax:
E-mail:
Internet:
ISIN: US9901966690
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
CN Creative Ltd.
04.04.2012 11:00
---------------------------------------------------------------------------
MANCHESTER, England, 2012-04-04 11:00 CEST (GLOBE NEWSWIRE) --
CN Creative, Ltd. (CNC), a healthcare company providing innovative and
sustainable solutions to reduce smoking and smoking-related illnesses, today
announced that Tim Byrne has been appointed Chief Financial Officer.
Mr. Byrne, who is a Fellow of the Institute of Chartered Accountants, is an
accomplished financial executive whose experience ranges from start-up ventures
to international publicly listed companies. Most recently, he was a Founding
Partner of The Management Alliance, which provides strategic and financial
consulting and management services. Previously, Mr. Byrne was CEO and CFO of
Airtours plc, a FTSE 250 listed company with diversified global operations and
an annual turnover of [Pounds]5.2 billion.
CN Creative markets a portfolio of products and services for smoking cessation
and harm reduction. The company's Nicadex(tm) electronic inhaler nicotine
replacement therapy (NRT) is to commence clinical trials shortly and the
company intends to submit a Marketing Authorisation Application to the UK
Medicines and Healthcare products Regulatory Agency (MHRA) later this year.
Regulatory submissions in other European territories and the US will follow.
'Tim's extensive experience in growing global firms is proving invaluable, and
we are delighted to have him as part of CNC's management team,' said David
Newns, co-founder and Company Director of CN Creative. 'His broad expertise is
especially helpful as we are advancing our pioneering electronic inhaler
nicotine replacement therapy towards MHRA submission, while also expanding our
existing businesses in the UK and overseas.'
Dale R. Pfost, PhD, Chairman of CN Creative and a General Partner at Advent
Ventures, commented, 'Tim brings us a global financial perspective and a keen
appreciation of how to manage the challenges of high growth companies, and he
is well-grounded in the nuts and bolts of implementing the financial management
systems critical to our success.'
About CN Creative
CN Creative has developed a portfolio of products and services focused on harm
reduction and smoking cessation, including user-friendly nicotine delivery
systems and patient-focused smoking cessation and support services, such as
QuitDirect, the Intellicig(r) electronic cigarette, ECOpure high purity nicotine
preparations and NRT Direct. CNC's Nicadex(tm) electronic inhaler nicotine
replacement therapy product is in development for use as part of medically
supervised smoking cessation programmes. For more information, visit
www.cncbio.co.uk.
CONTACT: CN Creative
Media
Barbara Lindheim, BioCom Partners
blindheim@biocompartners.com, +1 212 584-2276
Corporate
David Newns, CN Creative
david.newns@cncbio.com, +44 (0) 7834 767 367
News Source: NASDAQ OMX
04.04.2012 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: CN Creative Ltd.
GroÃbritannien
Phone:
Fax:
E-mail:
Internet:
ISIN: US9901966690
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------